Abnormal Protac-induced coagulation inhibition chromogenic assay results are associated with an increased risk of recurrent venous thromboembolism

Journal of Thrombosis and Thrombolysis

Volumn 30, Issue 2, 2010, Pages 215-219

  Tripodi, Armando ^a   Legnani, Cristina ^a,b   Lemma, Laura ^a   Cosmi, Benilde ^a,b   Palareti, Gualtiero ^a,b   Chantarangkul, Veena ^a   Mannucci, Pier Mannuccio ^a  

^a UNIVERSITY OF MILAN   (Italy)

^b UNIVERSITY OF BOLOGNA   (Italy)

Author keywords

Hypercoagulability; Protein C anticoagulant pathway; Thrombin generation; Thrombophilia

Indexed keywords

ANTIVITAMIN K; BLOOD CLOTTING FACTOR 5; PROTEIN C; THROMBOMODULIN; ANTICOAGULANT AGENT; BIOLOGICAL MARKER; CHROMOGENIC SUBSTRATE; FIBRINOLYTIC AGENT; PEPTIDE; SNAKE VENOM PROTEIN C ACTIVATOR; THROMBIN; THROMBOPLASTIN; VITAMIN K GROUP;

ADULT; AGED; ARTICLE; ASSAY; CAUSAL ATTRIBUTION; CONTROLLED STUDY; DISEASE FREE SURVIVAL; FEMALE; GENE MUTATION; HUMAN; INCIDENCE; MAJOR CLINICAL STUDY; MALE; PREDICTION; PRIORITY JOURNAL; PROTAC INDUCED COAGULATION INHIBITION ASSAY; PROTEIN BLOOD LEVEL; RECURRENT DISEASE; RISK ASSESSMENT; RISK FACTOR; THROMBIN TIME; VENOUS THROMBOEMBOLISM; ANTAGONISTS AND INHIBITORS; BLOOD; BLOOD CLOTTING; BLOOD CLOTTING TEST; CLINICAL TRIAL; DIAGNOSTIC USE; DRUG ADMINISTRATION; DRUG EFFECTS; ITALY; KAPLAN MEIER METHOD; METABOLISM; MIDDLE AGED; MULTICENTER STUDY; PREDICTIVE VALUE; PROPORTIONAL HAZARDS MODEL; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL; TIME; TREATMENT OUTCOME; VERY ELDERLY; YOUNG ADULT;

ADULT; AGED; AGED, 80 AND OVER; ANTICOAGULANTS; BIOLOGICAL MARKERS; BLOOD COAGULATION; BLOOD COAGULATION TESTS; CHROMOGENIC COMPOUNDS; DRUG ADMINISTRATION SCHEDULE; FEMALE; FIBRINOLYTIC AGENTS; HUMANS; ITALY; KAPLAN-MEIERS ESTIMATE; MALE; MIDDLE AGED; PEPTIDES; PREDICTIVE VALUE OF TESTS; PROPORTIONAL HAZARDS MODELS; PROSPECTIVE STUDIES; PROTEIN C; RECURRENCE; RISK ASSESSMENT; RISK FACTORS; THROMBIN; THROMBOPLASTIN; TIME FACTORS; TREATMENT OUTCOME; VENOUS THROMBOEMBOLISM; VITAMIN K; YOUNG ADULT; KAPLAN-MEIER ESTIMATE;

EID: 77957970510     PISSN: 09295305     EISSN: None     Source Type: Journal    
DOI: 10.1007/s11239-010-0479-z     Document Type: Article

References (21)

1. Cushman M, Tsai AW, White RH, Heckbert SR, Rosamond WD, Enright P, Folsom AR (2004) Deep vein thrombosis and pulmonary embolism in two cohorts: the longitudinal investigation of thromboembolism etiology. Am J Med 117:19-25
2. Prandoni P, Lensing AW, Cogo A, Cuppini S, Villalta S, Carta M, Cattelan AM, Polistena P, Bernardi E, Prins MH (1996) The long-term clinical course of acute deep venous thrombosis. Ann Intern Med 125:1-7
3. Palareti G, Legnani C, Cosmi B, Guazzaloca G, Pancani C, Coccheri S (2002) Risk of venous thromboembolism recurrence: high negative predictive value of D-dimer performed after oral anticoagulation is stopped. Thromb Haemost 87:7-12
4. Eichinger S, Minar E, Bialonczyk C, Hirschl M, Quehenberger P, Schneider B, Weltermann A, Wagner O, Kyrle PA (2003) D-dimer levels and risk of recurrent venous thromboembolism. JAMA 290:1071-1074 (Pubitemid 37430448)
5. Hron G, Kollars M, Binder BR, Eichinger S, Kyrle PA (2006) Identification of patients at low risk for recurrent venous thromboembolism by measuring thrombin generation. JAMA 296:397-402
6. van Hylckama Vlieg A, Christiansen SC, Luddington R, Cannegieter SC, Rosendaal FR, Baglin TP (2007) Elevated endogenous thrombin potential is associated with an increased risk of a first deep venous thrombosis but not with the risk of recurrence. Br J Haematol 138:769-774 (Pubitemid 47313221)
7. Tripodi A, Legnani C, Chantarangkul V, Cosmi B, Palareti G, Mannucci PM (2008) High thrombin generation measured in the presence of thrombomodulin is associated with an increased risk of recurrent venous thromboembolism. J Thromb Haemost 6:1327-1333
8. Besser M, Baglin C, Luddington R, van Hylckama Vlieg A, Baglin T (2008) High rate of unprovoked recurrent venous thrombosis is associated with high thrombin-generating potential in a prospective cohort study. J Thromb Haemost 6:1720-1725
9. Legnani C, Palareti G, Cosmi B, Cini M, Tosetto A, Tripodi A, for the PROLONG Investigators (on behalf of FCSA, Italian Federation of Thrombosis Centers) (2008) Different cut off values of D-dimer methods to establish duration of oral anticoagulation after venous thromboembolism. Haematologica 93:900-907
10. Palareti G, Cosmi B, Legnani C, Tosetto A, Brusi C, Iorio A, Pengo V, Ghirarduzzi A, Pattacini C, Testa S, Lensing AWA, Tripodi A (2006) D-Dimer test to establish duration of anticoagulation after a first idiopathic episode of venous thromboembolism; the prospective randomized "Prolong" study. N Engl J Med 355:1780-1789
11. Toulon P, Smirnov M, Triscott M, Safa O, Biguzzi E, Bouziane K, Tripodi A (2009) A new chromogenic assay (HemosIL ThromboPath) is sensitive to major prothrombotic risk factors affecting the protein C Pathway. Results of a multicenter study. Thromb Res 124:137-143
12. Kyrle PA, Minar E, Hirschl M, Bialonczyk C, Stain M, Schneider B, Weltermann A, Speiser W, Lechner K, Eichinger S (2000) High plasma levels of factor VIII and the risk of recurrent venous thromboembolism. N Engl J Med 343:457-462 (Pubitemid 30646484)
13. Eichinger S, Pabinger I, Stümpflen A, Hirschl M, Bialonczyk C, Schneider B, Mannhalter C, Minar E, Lechner K, Kyrle PA (1997) The risk of recurrent venous thromboembolism in patients with and without factor V Leiden. Thromb Haemost 77:624-628
14. Lindmarker P, Schulman S, Sten-Linder M, Wiman B, Egberg N, Johnsson H (1999) The risk of recurrent venous thromboembolism in carriers and non-carriers of the G1691A allele in the coagulation factor V gene and the G20210A allele in the prothrombin gene. DURAC Trial Study Group. Duration of Anticoagulation. Thromb Haemost 81:684-689
15. Kearon C, Gent M, Hirsh J, Weitz J, Kovacs MJ, Anderson DR, Turpie AG, Green D, Ginsberg JS, Wells P, MacKinnon B, Julian JA (1999) A comparison of three months of anticoagulation with extended anticoagulation for a first episode of idiopathic venous thromboembolism. N Engl J Med 340:901-907 (Pubitemid 29141050)
16. Baglin T, Luddington R, Brown K, Baglin C (2003) Incidence of recurrent venous thromboembolism in relation to clinical and thrombophilic risk factors: prospective cohort study. Lancet 362:523-526
17. Christiansen SC, Cannegieter SC, Koster T, Vandenbroucke JP, Rosendaal FR (2005) Thrombophilia, clinical factors, and recurrent venous thrombotic events. JAMA 293:2352-2361
18. Ridker PM, Miletich JP, Stampfer MJ, Goldhaber SZ, Lindpaintner K, Hennekens CH (1995) Factor V Leiden and risks of recurrent idiopathic venous thromboembolism. Circulation 92:2800-2802
19. Simioni P, Prandoni P, Lensing AW, Manfrin D, Tormene D, Gavasso S, Girolami B, Sardella C, Prins M, Girolami A (2000) Risk for subsequent venous thromboembolic complications in carriers of the prothrombin or the factor V gene mutation with a first episode of deep-vein thrombosis. Blood 96:3329-3333
20. Toulon P, Perez P, Rapp J, Add R (2007) An abnormal ProC global test results is associated with an increased risk of venous thromboembolism independent of test sensitivity for protein C pathway abnormalities. Thromb Haemost 98:228-233
21. Eichinger S, Hron G, Hirschl M, Bialonczyk C, Minar E, Kollars M, Kyrle PA (2007) Prediction of recurrent venous thromboembolism by measuring ProC Global. Thromb Haemost 98:1232-1236